Ask your doctor about BENLYSTA, the first FDA-approved treatment for lupus in over 50 years.
BENLYSTA is the first prescription treatment in over 50 years approved for adults with active, systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines. BENLYSTA is not a steroid—it's a biologic therapy, delivered through an intravenous (IV) infusion. It works by reducing certain cells in your immune system that can make lupus active.
Studies have found that adding BENLYSTA to commonly used lupus medications can reduce lupus disease activity. In fact, in clinical trials, BENLYSTA plus other lupus treatments was superior to other lupus treatments alone in reducing lupus disease activity. It is not known if BENLYSTA is safe and effective in people with severe active lupus nephritis or severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.
- not a steroid
- added to your other lupus medications
- given by intravenous (IV) infusion
- the first lupus treatment approved by the FDA in over 50 years
Susan, Morgan and Michelle discuss how they felt about the possibility of receiving treatments with BENLYSTA.
GSK sponsors ambassadors for BENLYSTA and pays them for their time and expense in sharing their experiences.
Individual results may vary.
History of BENLYSTA
BENLYSTA is the first FDA-approved medication in over 50 years to treat adults with active lupus. It is the first in a drug class known as BLyS-specific inhibitors.
In 1996, researchers identified a naturally occurring protein in the human body called BLyS (pronounced "bliss"), short for B-lymphocyte stimulator. Clinical studies showed there was a connection between higher levels of BLyS and lupus disease activity in some people. BENLYSTA binds to BLyS and prevents it from stimulating B cells.
FDA approved BENLYSTA on March 9, 2011, providing an additional option to treat lupus.